MedTrace Logo

A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

NCT05787561 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-28

No results posted yet for this study

Summary

This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.

Conditions

  • Mesonephric Gynecologic Cancer

Interventions

DRUG

Avutometinib (VS-6766)

3.2 mg PO, twice weekly

DRUG

Defactinib

200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.

Sponsors & Collaborators

Principal Investigators

  • Rachel Grisham, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2027-03-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05787561 on ClinicalTrials.gov